GlassScriptPhysician profile
Naomi E Ufberg
NPI 1396062196
$1,946.76
in general payments reported to CMS, 2019-2025
31 companies · $295 in 2025
The $295 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $253 · 2020: $173 · 2021: $316 · 2022: $381 · 2023: $314 · 2024: $215 · 2025: $295.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $811 · Education: $13.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $810.50 |
| Education | $13.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $233.51 | 2019-2025 | Lo Loestrin Fe |
| Mayne Pharma Commercial LLC | $181.45 | 2022-2024 | |
| Coopersurgical, INC. | $156.59 | 2019-2025 | Paragard T 380a, Paragard T 380a |
| Therapeuticsmd, INC. | $149.36 | 2019-2022 | |
| Organon LLC | $113.05 | 2022-2023 | Nexplanon |
| Astellas Pharma US INC | $106.40 | 2024-2025 | Veozah |
| Scynexis, INC. | $84.04 | 2022 | |
| Agile Therapeutics, INC. | $82.59 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $81.31 | 2020-2023 | |
| Smith+Nephew, INC. | $78.69 | 2022-2025 | Pico 14 |
| Millicent US INC | $76.76 | 2024-2025 | Intrarosa, Femring, Femlyv |
| Myovant Sciences INC. | $73.10 | 2021-2022 | |
| Exeltis, USA INC. | $70.12 | 2022-2025 | Slynd |
| Sumitomo Pharma America, INC. | $68.09 | 2023-2024 | Myfembree |
| Hologic Sales and Service, LLC | $65.77 | 2021-2023 | Aptima, Affirm Prone Biopsy System |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $53.02 | 2019-2021 | |
| Biogen, INC. | $31.28 | 2025 | Zurzuvae |
| Lupin INC. | $31.17 | 2019 | |
| Roche Diagnostics Corporation | $22.61 | 2021 | |
| Shield Therapeutics INC | $21.38 | 2025 | |
| Mission Pharmacal Company | $19.24 | 2021 | |
| Mylan Pharmaceuticals INC. | $18.71 | 2020 | |
| Kerecis Limited | $16.84 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Vertical Pharmaceuticals, LLC | $16.54 | 2019 | |
| Amgen INC. | $16.04 | 2025 | Prolia, Evenity |
| Medicem INC. | $16.00 | 2020 | |
| Pfizer INC. | $14.81 | 2023 | |
| Aspira Women'S Health INC | $13.41 | 2019 | |
| Amag Pharmaceuticals, INC. | $12.05 | 2019 | |
| Avion Pharmaceuticals | $11.44 | 2019 | |
| Merck Sharp & Dohme LLC | $11.39 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Naomi Ufberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.